期刊文献+

三氧化二砷与阿糖胞苷联合治疗骨髓增生异常综合征38例疗效观察 被引量:9

Clinical observation on Arsenic Trioxide combined with Cytarabine in the treatment of 38 patients with myelodysplastic syndrome
下载PDF
导出
摘要 目的观察三氧化二砷与阿糖胞苷联合治疗骨髓增生异常综合征的临床疗效。方法将我院确诊的76例骨髓增生异常综合征患者随机分为治疗组和对照组,每组各38例。治疗组给予阿糖胞苷(Ara-c)+三氧化二砷(As2O3)治疗。对照组采用传统的HA方案,三尖杉酯碱(H)和阿糖胞苷(A)治疗。两组患者均给予相同的支持治疗,即血红蛋白<70 g/L,血小板<30×109/L,输注血小板悬液或新鲜血;有感染者给予抗细菌、抗病毒及抗霉菌药物治疗;同时,注意保护肝、肾功能。两组患者均治疗3个疗程。结果治疗组总有效率为89.47%,对照组总有效率为71.05%,两组总有效率比较差异有统计学意义(P<0.05)。两组患者治疗血清血管内皮生长因子(VEGF)水平与治疗前比较,均明显下调,差异均有高度统计学意义(P<0.01);治疗后,治疗组VEGF下调明显优于对照组,两组比较差异有高度统计学意义(P<0.01)。结论三氧化二砷与阿糖胞苷联合治疗能够提高骨髓增生异常综合征患者三系血细胞,使骨髓原始细胞数减少,改善血液学反应,且耐受性高,不良反应少,是一种有效的骨髓增生异常综合征治疗方法。 Objective To observe the treatment effect of Arsenic Trioxide(As2O3) combined with Cytarabine(Ara-c) in the treatment of myelodysplastic syndrome(MDS).Methods 76 patients with definite MDS were randomly divided into the treatment group and the control group,with 38 cases in each group.In the treatment group,Ara-c combined with As2O3 was used;while in the control group,traditional HA(Harringtonine and Ara-c) regimen was selected.The same supportive treatment was given in each group,that was transfusing platelet suspension or fresh blood to those with platelet of 30×109/L or HB of 70 g/L;giving anti-bacterial,anti-viral and anti-fungal treatment when there was infection;meanwhile the liver and kidney function were took good care.The patients in both groups were treated for three courses.Results Comparing the treatment effect between the two groups,the total effective rate of the treatment group was 89.47%,while that of the control group was 71.05%;there was significant difference in the two groups(P 0.05).The vascular endothelial growth factor(VEGF) level were obviously down regulated after treatment in both groups and the differences were significant(P 0.01);after treatment,the VEGF level was significantly down regulated in the treatment group than that in the control group(P 0.01).Conclusion As2O3 combined with Ara-c for MDS can increase the number of three lines of blood cells,decrease the initial cell number of bone marrow,and improve the haematological reaction;meanwhile,the regimen had a high tolerance and little side effect.On the whole,As2O3 combined with Ara-c is an effective treatment for MDS.
出处 《中国医药导报》 CAS 2012年第9期80-81,84,共3页 China Medical Herald
  • 相关文献

参考文献7

二级参考文献30

  • 1张传海,许戈良,傅斌生.三氧化二砷抗肿瘤作用机制研究进展[J].蚌埠医学院学报,2006,31(2):219-220. 被引量:1
  • 2卢洁,金洁.三氧化二砷体内诱导人骨髓增生异常综合征荷瘤小鼠细胞凋亡机制的研究[J].中华儿科杂志,2006,44(10):782-786. 被引量:5
  • 3CHESON B D,GREENBERG P L,BENNETT J M,et al.Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia[J].Blood,2006,108:419-425.
  • 4BARZI A,SEKERES M A.Myelodysplastic syndrom-es:a practical approach to diagnosis and treatment[J].Cleve Clin J Med,2010,77:37-44.
  • 5SEKERES M A.New data with arsenic trioxide in leukemias and myelodysplastic syndromes[J].Clin Lymphoma Myeloma,2007,8:S7-S12.
  • 6SCHILLER G J,SLACK J,HAINSWORTH J D,et al.Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes[J].J Clin Oncol,2006,24:2456-2464.
  • 7VEY N,BOSLY A,GUERCI A,et al.Arsenic trioxide in patients with myelodysplastic syndromes:a phase II multicenter study[J].J Clin Oncol,2006,24:2465-2471.
  • 8LAFFITTE E,REVUZ J.Thalidomide:an old drug with new clinical applications[J].Expert Opin Drug Saf,2004,3:347-356.
  • 9RAZA A,MEYER P,DUTT D,et al.Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes[J].Blood,2001,98:958-965.
  • 10ZORAT F,SHETTY V,DUTT D,et al.The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes[J].Br J Haematol,2001,115:881-894.

共引文献28

同被引文献81

  • 1易雪,余丹,张婷,邹亮,程辉.地西他滨联合CHG方案诱导化疗骨髓增生异常综合征转化急性髓系白血病的疗效观察[J].医学信息(医学与计算机应用),2014(18):107-108. 被引量:3
  • 2马俊丽,曲文闻,胡晓梅.砷制剂在骨髓增生异常综合征治疗中的应用[J].中华临床医师杂志(电子版),2012,6(16):4819-4821. 被引量:13
  • 3周帆,侯健,韦苇,张忆梓,游丽芳,杨盛玲,张永贞.三氧化二砷联合沙利度胺治疗骨髓增生异常综合征的初步临床观察[J].国际输血及血液学杂志,2006,29(1):6-8. 被引量:10
  • 4钱思轩,王莉,卢瑞南,等.C25地西他滨联合粒细胞集落刺激因子、小剂量阿克拉霉素和阿糖胞苷治疗老年骨髓增生异常综合征的疗效观察[C]//中华医学会第十二次全国血液学学术会议论文集,2012:246-247.
  • 5Chen SJ,Zhou GB,Zhang XW.From an old remedy to a magic bullet:molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia[J].Blood,2011,117(24):6425-6435.
  • 6Keyhani M.Use of arsenic trioxide as a first-line single agent in the treatment of acute promyelocytic leukemia[J].J Clin Oncol,2012,30(2):217-222.
  • 7Lengfelder E,Hofmann WK,Nowak D.Impact of arsenic trioxide in the treatment of acute promyelocytic[J].Leukemia,2012,26(3):433-442.
  • 8Lo-Coco F,Avvisati G,Vignetti M,et al.Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia[J].NEJM,2013,369(2):111-121.
  • 9Lengfelder E,Hofmann WK,Nowak D.Impact of arsenic trioxide in the treatment of acute promyelocytic[J].Leukemia,2012,26(3):433-442.
  • 10Liu Y, Bao EN, Yang B, ct al. Clinical study of autologous cytokine induced killer cell infusion treating for elderly patients, with myelodysplastic syndrome[J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 20l 1, 19(3): 787-792.

引证文献9

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部